Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T35940 | Target Info | |||
| Target Name | ERK activator kinase 1 (MEK1) | ||||
| Synonyms | PRKMK1; Mitogen-activated protein kinase kinase 1; MKK1; MEK 1; MAPKK 1; MAPK/ERKkinase 1; MAPK/ERK kinase 1; MAP kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1 | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | MAP2K1 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| European Patent Office (EPO) | |||||
| Patent ID | EP3061747 | ||||
| Title | Pyridic Ketone Derivatives, Method of Preparing Same, and Pharmaceutical Application Thereof. | ||||
| Applicant(s) | Shanghai Hengrui Pharm | ||||
| Representative Drug(s) | D0XW4G | Drug Info | IC50 < 10 nM | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.